The anti-inflammatory approach to septic shock

Intensivmedizin und Notfallmedizin

Volumn 34, Issue 2, 1997, Pages 101-109

  Eichacker, P Q ^a   Natanson, C ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

adhesion molecule; G CSF; immunomodulators; inflammation; neutrophil; sepsis; septic shock

Indexed keywords

ANTIINFLAMMATORY AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ESCHERICHIA COLI; HUMAN; IMMUNOMODULATION; INFLAMMATION; LEUKOCYTE; NONHUMAN; REVIEW; SEPSIS; SEPTIC SHOCK;

EID: 0030756435     PISSN: 01753851     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003900050026     Document Type: Review

References (34)

1. Beutler B, Milsark IW, Cerami AC (1985) Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effects of endotoxemia. Science 229:869-871
2. Natanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL (1994) Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 120:771-783
3. Eichacker PQ, Natanson C (1996) Rethinking the anti-inflammatory approach to septic shock. In: Vincent J-L (ed) Yearbook of Intensive Care and Emergency Medicine. Springer-Verlag: Berlin, Heidelberg, New York, pp 165-175
4. Fisher CJ, Opal SM, and Dhainaut J (1993) Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 21:318-325
5. Abraham E, Wunderink R, Silverman H, et al (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. JAMA 273:934-941.
6. Carlet, et al (1994) Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy 34, 7. New Orleans, Louisiana
7. Reinhart K, Wiegand-Lohnert C, Grimminger F, et al (1996) Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter. randomized, placebo-controlled, dose-ranging study. Crit Care Med 24:733-739
8. Dhainaut J, Vincent J, Richard C, et al (1995) CDP571, a humanized antibody to tumor necrosis factor alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. Crit Care Med 23:1461-1467
9. Fisher CJ, Agosti J, Opal SM (1996) Treatment of septic shock with the tumor necrosis factor receptor.Fc fusion protein. New Engl J Med 334: 1697-1702
10. Abraham, E (1995) Ro 45-2081 (TNFR55-IgGl) in the treatment of patients with severe sepsis and septic shock: preliminary results. Presented at the Second International Autumnal Thematic Meeting on Sepsis. Deauville, France
11. Fisher CJ, Slotner GJ, Opal SM, et al (1994) Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 22:12-21
12. Fisher CJ, Dhainaut JA, Opal SM, et al (1994) Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA 271:1836-1844
13. Opal SM (1996) Role of IL1-1ra: results of a second phase III trial. Presented at the 16th International Symposium on Intensive Care and Emergency Medicine. Brussels, Belgium
14. Dhainaut JFA, Tenaillon A, Le Tulzo Y, et al (1994) Platelet activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 22:1720-1728
15. Dhainaut JFA, Tenaillon A, Hemmer M, et al (1995) Confirming phase III clinical trial to study the efficacy of a PAF antagonist, BN 52021, in reducing mortality of patients with severe gramnegative sepsis. Am J Respir Crit Care Med 151:A447
16. Cortech press release (1994) Denver, Colorado
17. Cortech press release (1995) Denver, Colorado
18. Wheeler AP, Carmichael L, Christman B, et al (1996) Characteristics and outcome from the Ibuprofen Sepsis Study Group. Am J Respir Crit Care Med 153:A123
19. Lefering R, Neugebauer EAM (1995) Steroid controversy in sepsis and septic-shock: a meta-analysis. Crit Care Med 23:1294-1303
20. Cronin L, Cook DJ, Carlet J, et al (1995) Corticosteroid treatment for sepsis: a critical appraisal and metaanalysis of the literature. Crit Care Med 23:1430-1439
21. Eichacker PQ, Hoffman WD, Farese A, et al (1992) Leukocyte CD11b/18 antigen directed monoclonal antibody prolongs survival and decreases hypoxemia in canines challenged with tumor necrosis factor. Am Rev Respir Dis 145:1023-1029
22. Natanson C, Eichenholz PW, Danner RL, et al (1989) Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 169:823-832
23. Eichacker PQ, Hoffman WD, Farese A, et al (1991) Tumor necrosis factor but not interleukin-1 challenge in canines produces lethal pulmonary injury and sustained but reversible multiple organ dysfunction similar to human septic shock. J Appl Physiol 71:1979-1986
24. Eichenholz PW, Eichacker PQ, Banks SM, et al (1992) Tumor necrosis factor challenges produce cardiovascular abnormalities in does. Am J Physiol (Heart Circ Physiol) 263:H668-H675
25. Freeman BD, Correa R, Karzai W, et al (1996) Controlled trials of granulocyte colony stimulating factor or CD11b directed MAb during hyperoxia and E. coli pneumonia in rats. J Appl Physiol, in press
26. Eichacker PQ, Hoffman WD, Farese A, et al (1993) Monoclonal antibody against leukocyte CD 11/18 adhesion complex worsens endotoxemia and cardiovascular dysfunction in antibiotic-treated canines with septic shock. J Appl Physiol 74(4): 1885-1892
27. Quezado MJN, Quezado ZMN, Zeni F, et al (1996) G-CSF improves and CD11/18 MAb worsens hemodynamics independently during endotoxemia in canines. Am J Resp Crit Care Med 153:A838
28. Fontana J, Zeai F, Correa R, et al (1996) Inhibition of leukocyte CD11b and endothelial ICAM-1 in E. coli pneumonia. Am J Resp Crit Care Med 153:A444
29. Zeni F, Fontana J, Correa R, et al (1996) ICAM-I directed MAb reduces survival during E. coli pneumonia in rats. Am J Resp Crit Care Med 153:A258
30. Quezado ZMN, Hoffman WD, Winkelstein JA, et al (1994) The third component of complement protects against endotoxin-induced shock and multiple organ failure. J Exp Med 179:569-578
31. Eichacker PQ, Waisman Y, Natanson C, et al (1994) The cardiopulmonary effects of granulocyte colony-stimulating factor in a canine model of bacterial peritonitis. J Appl Physiol 77:2366-2373
32. Zeni F, Freeman B, Quezado MJN, et al (1996) Prophylactic G-CSF improves myocardial function and survival but not lung injury in canine E. coli pneumonia and sepsis. Am J Resp Crit Care Med 153:A838
33. Eichacker P, Quezado MJN, Zeni F, et al (1996) G-CSF increases or decreases the relative risk of death dependent on site and severity of infection in rats. Am J Resp Crit Care Med 153:A252
34. Quezado ZMN, Natanson C, Hoffman WD, et al (1995) Granulocyte colony stimulating factor (G-CSF) treatment at the onset of E. coli-peritonitis-induced septic shock in canines. Am J Resp Crit Care Med 151:A447